Vertex Pharmaceuticals
NEWS
For those looking for work, it’s good to know that some positions are in such demand that employers are falling all over themselves to offer hiring incentives. That’s the case with the biotech sector in Massachusetts, as many companies are dangling almost unheard-of benefits as incentives.
In May the FDA placed a hold on the trial and IND for CTX001, an investigational gene editing treatment, citing concerns over questions that had not been addressed in the IND.
Here’s a look at who’s making moves in the biotech and pharma world this week.
Belgium-based Galapagos NV snagged $300 million following its U.S. public offering of new ordinary shares in the form of American Depositary Shares.
As we move into the last quarter of 2018, plenty of companies are looking at potential catalysts. George Budwell, writing for The Motley Fool, takes a look at three potentially high-reward biotech companies, but along with their big catalysts comes high risk.
Cystic fibrosis drugmaker Vertex Pharmaceuticals forged a three-year collaborative deal with U.K.-based machine learning specialist Genomics plc to improve the discovery of targets for precision medicines.
Massachusetts in general and Boston, specifically Cambridge, is one of the two largest centers in the U.S. for biotech startups and life science companies (the other being the San Francisco Bay Area). Here’s a look at 13 Massachusetts life science companies that are showing both gains and losses—mostly gains—at the six-month mark.
This week had three important target action dates, known as Prescription Drug User Fee Act (PDUFA) dates, for the U.S. Food and Drug Administration (FDA). The agency got ahead of its schedule and approved all of these drugs ahead of schedule. Let’s take a look.
This week, the Business Journals compiled a list of the 25 companies across the United States with the highest median salary for employees. According to the list, median salaries for these companies ranked from $198,000 to $495,000. Of those companies listed, more than half were in the pharma or biotech industries.
JOBS
IN THE PRESS